Novavax Public Company
Formerly called Isconova, Novavax, Inc. is a public, clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, it produces vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Novavax's vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis. fThe company's product pipeline targets a variety of infectious diseases, with clinical vaccine candidates for respiratory syncytial virus (RSV), seasonal influenza and Ebola virus (EBOV) and a preclinical program for a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.
Select investors Bill & Melinda Gates Foundation
Last update: May 13, 2018
Disclaimer: We can not guarantee that the information on this page is 100% correct. more